Last Updated: March 27, 2026, 8 am UTC

Recent regulatory developments are reshaping how sponsors think about evidence, oversight, and operational readiness. In a New England Journal of Medicine Sounding Board, FDA leadership announced that one adequate and well-controlled clinical trial — supported by confirmatory evidence — could become the agency’s new default standard for approval.ⁱ The shift formally moves away from the long-standing expectation of two pivotal trials and places greater emphasis on study quality, scientific credibility, and the totality of evidence.

In the first blog of this series, we examined what this change signals for drug development more broadly. In the second, we explored the operational implications for Trial Master File (TMF) strategy and inspection readiness.

This final installment looks ahead. As regulatory flexibility expands in some areas, expectations around execution, documentation, safety reporting, manufacturing readiness, and technology infrastructure are becoming more exacting. Success will depend less on the number of trials conducted and more on disciplined planning, clear documentation, and alignment across functions.

Across the industry, a consistent theme is emerging: preparation, clarity, and cross-functional coordination are now central to regulatory success. Below are five key trends sponsors should consider as they plan their next phase of development.

AI in Regulatory Development: A Tool to Support, Not Replace

Artificial intelligence continues to generate interest, but expectations are becoming more grounded. AI is increasingly viewed as a support tool rather than a substitute for expertise.

Current applications focus on drafting early versions of documents, summarizing data, and supporting quality checks such as proofreading and consistency review. These uses can improve efficiency, but they do not replace regulatory judgment or scientific oversight.

Regulators have reinforced that sponsors remain fully accountable for all submitted content. AI-generated outputs must be carefully reviewed, validated, and aligned with regulatory standards. In 2026, the emphasis will be less on adopting AI and more on applying it responsibly, transparently, and in ways that support science-based decision making and thereby strengthen regulatory confidence.

Organizations are also recognizing the importance of establishing internal governance frameworks for AI use by defining what applications are appropriate for AI; establishing validation processes to vet results; setting documentation standards and defining oversight responsibilities. Clear audit trails, version control, and human-in-the-loop review processes will be critical in demonstrating control and ensuring that AI is a value add and not a liability. As regulatory authorities increasingly inquire about data provenance and content generation methods, sponsors should be prepared to explain not only what AI was used for, but how outputs were verified before submission.

FDA Capacity and the Review Experience

Agency resourcing continues to influence review practices at the Agency and is highlighting the need for active engagement with the review divisions. While FDA remains committed to meeting its statutory obligations, staffing shifts and evolving workloads are shaping how interactions unfold. Sponsors may notice longer agency response times to some types of filing amendments and queries, greater reliance on established guidance, and more meaningful responses only for targeted and well-defined proposals. This reinforces the importance of submitting clear, well-supported documentation that aligns closely with existing frameworks. When deviations from established guidance are necessary, concise and well-structured justifications will be essential to ensuring meaningful feedback from the FDA.

As has been the case historically, early engagement is encouraged, and regulators continue to emphasize their openness to discussion. Presenting data and conclusions clearly—anticipating potential questions—can help facilitate productive interactions.

In this environment, predictability becomes a competitive advantage. Sponsors that invest time in thorough gap assessments, mock review exercises, and disciplined internal quality control processes may reduce the likelihood of avoidable information requests. Clear briefing packages, well-organized meeting materials, and focused objectives can help ensure that agency interactions are efficient and outcome-oriented.

Regulatory Strategy as Science Advances

Support for innovation remains strong, particularly for therapies addressing unmet needs. At the same time, as scientific understanding deepens in areas such as cell and gene therapies, regulatory expectations are becoming more refined.

Increased knowledge of mechanisms of action, safety considerations, and long-term outcomes is leading to more detailed data requests and strengthened oversight in certain areas. Expedited pathways continue to provide opportunity, but they do not replace the need for robust evidence.

For sponsors, this means pairing innovative science with thoughtful regulatory planning and comprehensive supporting data.

As regulators accumulate real-world experience with novel platforms, they are increasingly focused on durability of response, long-term follow-up strategies, and manufacturing consistency. Sponsors should anticipate more detailed discussions around comparability, potency assays, and control strategies—particularly when process changes occur during development.

Manufacturing Strategy and Pre-Marketing Safety Reporting Evolution

Manufacturing strategy is playing a more visible role in regulatory planning. U.S.-based manufacturing initiatives and related programs may offer enhanced engagement or review efficiencies for certain products.

While these opportunities can be advantageous, they operate within established regulatory standards. Quality, safety, and compliance expectations remain consistent. Coordinated planning across development, regulatory, and manufacturing teams will be key to maximizing potential benefits.

A notable operational shift in 2026 involves pre-marketing safety reporting. IND safety submissions are transitioning to electronic, machine-readable formats aligned with post-marketing reporting requirements. Individual Case Safety Reports (ICSRs) in XML format will increasingly replace traditional CIOMS or MedWatch submissions through publishing workflows. This evolution requires closer coordination between pharmacovigilance and regulatory operations teams to ensure smooth implementation.

Sponsors who proactively align vendors, systems, and internal processes will be better positioned to manage this transition efficiently. These manufacturing and safety reporting shifts highlight a broader trend: operational infrastructure is no longer peripheral to regulatory success – it is central to it. Early investment in scalable manufacturing processes, validated analytical methods, and digital reporting capabilities can prevent late-stage bottlenecks. Cross-functional communication between CMC, pharmacovigilance, regulatory affairs, and quality teams should be formalized rather than informal.

For global sponsors, harmonizing safety reporting workflows across regions will also be increasingly important. Aligning data standards and system configurations now can reduce duplication and minimize compliance risk as electronic reporting expectations continue to converge internationally.

Technology Infrastructure as a Strategic Enabler

Investment in Regulatory Information Management Systems (RIMS) and related platforms continues to grow. These systems are becoming central to managing submissions, documentation, and lifecycle data. As regulatory complexity increases, technology infrastructure is playing a larger role in supporting compliance and efficiency. While adoption varies across organizations, the trend toward integrated regulatory systems is clear.

Modern regulatory operations depend on accurate, accessible, and traceable data. Integrated platforms that connect submission planning, health authority correspondence, labeling management, and change control activities provide greater visibility and reduce reliance on fragmented spreadsheets or manual trackers. Over time, this infrastructure supports stronger inspection readiness and more agile lifecycle management.

Importantly, technology alone does not solve process inefficiencies. Successful implementation requires clearly defined workflows, standardized data taxonomies, and change management strategies that ensure consistent adoption across teams. Sponsors who treat technology transformation as a strategic initiative—rather than a software installation—are more likely to realize sustained value.

Planning for Success in 2026

Collectively, these trends point to an environment that rewards clarity, preparation, and collaboration. Sponsors who plan earlier, align closely with guidance, and present well-structured regulatory strategies will be well-positioned in the year ahead. Engaging regulators early, coordinating across functional teams, and using technology thoughtfully can help streamline development and maintain momentum. While many of these shifts are incremental, their combined impact will shape regulatory interactions throughout 2026 and beyond.

Connect with Premier Research’s regulatory experts to discuss how these trends may impact your 2026 plans.

ABOUT PREMIER RESEARCH:

Premier Research International LLC (Premier) is a global leader in clinical research and consulting services with expertise in driving an efficient and effective path to market for the life sciences industry.

Premier is built with the needs of biotech in mind, turning breakthrough science into life-changing drugs, devices, and diagnostics by addressing trial complexity, overcoming development hurdles, and demonstrating product value.

Leveraging deep therapeutic expertise, innovative technology, and product development operational proficiency—from preclinical planning to clinical trial execution and commercialization—our integrated approach offers personalized, end-to-end solutions to identify the pertinent data and insight necessary to make informed decisions earlier and deliver accelerated development timelines for a smarter, faster path to approval. To learn more visit premier-research.com.

REFERENCES

ⁱ Prasad V, Makary MA. One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma. N Engl J Med. 2026;394:815–817.